What You Need to Know
• Unique Pharmaceutical Laboratories is recalling generic Zyrtec due to potential cross-contamination with ranitidine.
• The recall affects cetirizine hydrochloride tablets USP 5 mg with lot numbers GY825029, GY825030, GY825031, and GY825032.
• Consumers may experience serious side effects if hypersensitive to ranitidine, including hypotension and difficulty swallowing.
Unique Pharmaceutical Laboratories is recalling a generic version of the allergy medication Zyrtec across the United States due to potential cross-contamination with ranitidine, a heartburn drug. The recall was announced on July 18, 2023, after a pharmacy technician noticed discoloration on some cetirizine hydrochloride tablets USP 5 mg during the packaging process. The affected products, distributed by Rising Pharma Holdings Inc., are packaged in 100-tablet bottles and have expiration dates set for October 2028. While there have been no reported adverse events related to this recall, the Food and Drug Administration warns that individuals sensitive to ranitidine may face severe health risks. Consumers with questions can contact Rising Pharma Holdings directly for further assistance.
Why It Matters
This recall highlights the importance of quality control in pharmaceutical manufacturing, particularly concerning cross-contamination risks. Ranitidine has been under scrutiny due to safety concerns, leading to its withdrawal from the market in 2020. The potential for serious side effects from contaminated medications underscores the need for vigilance among consumers and healthcare providers. Ensuring the safety of over-the-counter medications is crucial for public health, especially for individuals with specific sensitivities.
Read the Full Story →
